Clinical Report: Manufacturability and the Winners in Advanced Therapies

Overview

The report discusses the significant challenges in manufacturing cell and gene therapies, emphasizing the need for expertise and cost reduction strategies. It highlights the evolving landscape of drug development, where manufacturability has become the primary hurdle for advanced therapies.

Background

The transition from small molecules to biologics and now to cell and gene therapies marks a pivotal evolution in drug development. As these therapies promise potential cures, the complexity of manufacturing living medicines at scale presents new challenges. Understanding these challenges is crucial for ensuring that innovative therapies can reach patients effectively and affordably.

Data Highlights

No numerical or trial data provided in the article.

Key Findings

• Manufacturing challenges are now the rate-limiting step in the development of cell and gene therapies.
• Cost reduction in the development and production of advanced therapies is essential to broaden patient access.
• Investment in cell and gene therapy has become increasingly difficult, mirroring past economic downturns.
• The 'five Ps' framework (People, Patent, Product, Profit, and Potential) is critical for assessing the viability of therapy companies.
• Regulatory momentum is shifting towards more nuanced approaches for rare diseases, impacting therapy development.

Clinical Implications

Healthcare professionals must be aware of the manufacturing complexities associated with advanced therapies and the importance of having the right expertise in place. Additionally, understanding the financial landscape is vital for navigating funding challenges in this evolving field.

Conclusion

As the industry progresses, addressing manufacturability and cost issues will be key to the success of cell and gene therapies. Continuous adaptation to regulatory and funding environments will also be essential for innovation in this space.

References

1. The Medicine Maker, The Medicine Maker, 2026 -- Making – and Scaling – Advanced Medicines
2. The Medicine Maker, The Medicine Maker, 2026 -- Building Quality into Advanced Therapies from Day One
3. The Medicine Maker, The Medicine Maker, 2026 -- Manufacturing Inside the Patient
4. Bone Marrow Transplantation, Nature, 2025 -- Impact of Advanced Therapy Medicinal Product Regulations on Haematopoietic Stem Cell Transplantation Practices
5. Bone Marrow Transplantation, Nature, 2025 -- Indications for haematopoietic cell transplantation and CAR-T
6. FDA, FDA, 2025 -- Eliminates Risk Evaluation and Mitigation Strategies for Autologous CAR T cell Immunotherapies
7. PubMed, PubMed, 2026 -- Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4)
8. CancerNetwork, CancerNetwork, 2025 -- ZUMA-7 Final Analysis: Key Efficacy and Safety Findings
9. WFH gene therapy guidelines now published!
10. Gene therapy for sickle cell disease: Practice recommendations
11. Critical Juncture in Hemophilia Treatment: Global Organizations Issue Urgent Call to Action
12. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations | Bone Marrow Transplantation
13. FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies | FDA
14. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial - PubMed
15. ZUMA-7 Final Analysis: Key Efficacy and Safety Findings | CancerNetwork